Tavexia Lifecare to buy 60% Meyonex for ₹67.19 cr

Deal approved at October 7 board meeting

Tavexia Lifecare Limited said its board has approved the acquisition of up to 60% of the equity share capital of Meyonex Pharmaceuticals Limited for ₹67.19 crore. The decision was taken at the board meeting held on October 7, 2026, after reviewing valuation and due diligence reports for the target entity. The transaction is proposed to be executed through the subscription of fresh equity shares of Meyonex. The company said the acquisition is intended to expand its presence in the pharmaceutical sector. Meyonex Pharmaceuticals is an unlisted public company incorporated in India. The consideration remains subject to definitive documentation and applicable statutory and regulatory conditions. The company also indicated the acquisition could be completed in one or more tranches.

Structure: fresh issue subscription at ₹32 per share

The acquisition will be carried out by subscribing to 2,09,97,180 fresh equity shares of Meyonex at an issue price of ₹32 per share. Tavexia Lifecare said the proposed investment will be made entirely in cash mode. After completion of the fresh issue and allotment, Tavexia Lifecare will hold a controlling stake of 60% in Meyonex. Existing shareholders of Meyonex will retain the remaining 40% post-allotment. The post-allotment paid-up equity share capital of Meyonex is expected to stand at 3,49,95,300 shares. The company described the transaction as an equity investment rather than an asset transfer. It also clarified that the acquisition is not related to promoter group companies and does not constitute a slump sale.

Consideration and conditions precedent

Tavexia Lifecare disclosed a total consideration amount of ₹67,19,09,760 (₹67.19 crore). It said the consideration is subject to execution of definitive agreements and fulfillment of applicable statutory and regulatory conditions. While the board has approved the transaction framework, completion will depend on regulatory approvals that are currently pending. The company stated the transaction may be executed in one or more tranches, which can be relevant for cash-flow planning and procedural compliance. The October 7 meeting also reviewed the valuation and due diligence reports, signalling that internal review steps have been completed at the board level. No additional commercial terms beyond the price per share, number of shares, and stake percentage were disclosed in the provided information. The company has not indicated a specific completion date.

Funding plan: potential capital raise through multiple instruments

To finance the acquisition, the board approved in principle that Tavexia Lifecare may raise funds through various instruments. These include equity shares, warrants, debentures, or debt securities. The company said such fundraising could be done on a preferential issue or rights issue basis. Final decisions on quantum, size, and timing are to be determined later by the board, depending on market conditions. This indicates the acquisition funding plan is still being structured alongside the definitive deal documentation. The company has not specified whether the entire consideration will be funded through a single instrument or a mix. It also did not disclose any committed financing lines in the provided details. Investors will likely track subsequent board decisions for clarity on dilution, leverage, and timelines.

What changed since the September 7 preliminary approval

The October 7 approval follows an earlier board step taken on September 7, 2026, when Tavexia Lifecare authorised a preliminary evaluation of the proposed acquisition. At that stage, two directors were empowered to conduct due diligence, valuation, and negotiations, and no purchase price or binding terms were disclosed. The September 7 disclosures also stated that Meyonex had authorised capital of ₹20 crore and paid-up capital of about ₹14 crore. In addition, Tavexia Lifecare accepted the immediate resignation of SSRV & Associates and proposed Devam & Associates LLP as statutory auditor, subject to shareholder approval. The move from evaluation to an approved consideration value suggests the internal process progressed through diligence and valuation review ahead of the October 7 board decision. The company’s disclosures frame the October 7 meeting as the point where the board reviewed the due diligence and valuation reports and approved the transaction. Any remaining work now centres on definitive agreements, regulatory clearances, and allotment execution.

Governance and compliance: trading window closure and AGM items

Ahead of the board decision, Tavexia Lifecare had communicated that the trading window was closed from September 30, 2026, until 48 hours post-board meeting, in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015. The company also held its 46th Annual General Meeting on September 30, 2026, where it said all four proposed resolutions were passed. One special resolution approved material related party transactions up to ₹100 crore. In the context of an acquisition and possible fundraising, these governance disclosures matter because they outline the company’s compliance steps and shareholder authorisations already in place. The company has stated that the Meyonex transaction is not related to promoter group companies. It has also stated the transaction does not constitute a slump sale, which helps clarify deal classification. Regulatory approvals are still pending, which suggests further filings and clearances may follow.

Meyonex financial snapshot disclosed in the update

Alongside the acquisition approval, the provided information included a turnover snapshot for Meyonex. Meyonex reported FY25 turnover of ₹10.79 crore, down from ₹13.32 crore in FY24. This indicates a year-on-year decline in reported turnover based on the disclosed figures. Beyond these two years, no additional profitability, balance sheet, or segment data was provided. The target is described as an unlisted public entity incorporated in India, and earlier context referenced Maharashtra. Given the structure is a fresh issue, the proceeds from Tavexia Lifecare’s subscription would typically strengthen the target’s equity base post-allotment, subject to the company’s actual use of funds. The acquirer has positioned the transaction as a way to expand in the pharmaceutical sector, but no operational integration plan was disclosed.

Key deal terms at a glance

Timeline and disclosed reference points

Market impact: what investors can and cannot infer from disclosed facts

The most direct market-relevant information is the consideration amount, the equity subscription structure, and the funding flexibility the board has approved in principle. A cash acquisition of ₹67.19 crore is substantial relative to the company context described in the provided material, which also referenced Tavexia as a micro-cap with a market cap of approximately ₹1 crore and TTM revenue of ₹32 crore. Separately, the target’s reported turnover decline from FY24 to FY25 provides a limited but relevant snapshot of operating scale. The company has not disclosed expected synergies, profitability metrics, or post-deal financial guidance, so it is not possible to quantify earnings impact from the provided information. The board’s approval to raise funds through equity-linked instruments or debt securities indicates potential dilution or leverage, depending on the eventual mix. The fact that the transaction is subject to regulatory approvals and definitive agreements also means the timeline and final structure can still evolve. Investors will likely watch for subsequent filings on tranche structure, allotment completion, and fundraising terms.

Why the deal matters: control, capital infusion, and execution risk

By structuring the acquisition via a fresh issue, Tavexia Lifecare is seeking control through primary capital infusion rather than buying shares from existing holders. Post-allotment, the disclosed shareholding split would give Tavexia a controlling 60% stake, implying operational and governance influence at Meyonex. The company has explicitly stated the deal is not with promoter group companies, which addresses one common governance question in related transactions. Still, key execution dependencies remain, including definitive documentation and statutory and regulatory approvals. The board’s in-principle fundraising approval suggests management is preparing for the cash outlay, but the final funding route has not been decided. The transaction being executed in tranches can provide flexibility, but it can also extend timelines and add conditionality depending on how those tranches are structured. The next meaningful milestones, based on the company’s own disclosures, would be definitive agreements, regulatory clearances, and announcements related to funding and allotment.

Conclusion

Tavexia Lifecare’s board approval on October 7, 2026 sets a clear framework for acquiring up to 60% of Meyonex Pharmaceuticals for ₹67.19 crore through a cash subscription to fresh shares priced at ₹32 each. The deal is positioned as a move to expand the company’s pharmaceutical presence, but completion is contingent on definitive agreements and regulatory approvals. The board has also opened the door for fundraising through equity, warrants, debentures, or other debt securities via preferential or rights issues, with terms to be decided later. In the near term, investors will track subsequent disclosures on definitive documentation, the timing of tranches, regulatory clearances, and any capital-raising decisions tied to the acquisition.